Read by QxMD icon Read

Metastasic kidney cancer

Bartoš Vladimír
BACKGROUND: The tumor-to-tumor metastasis is exclusively rare finding, in which one malignant neoplasia metastasizes to another tumor of different origin. CASE: The author describes an 68-year-old woman, who was found to have a solitary tumor in the right kidney, as well as multiple tumor nodules in the liver. She underwent a radical nephrectomy. A histology of lesion in the kidney revealed a conventional clear cell renal cell carcinoma (RCC) harboring multiple metastatic foci of another adenocarcinoma...
2018: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
I Alex Bowman, Alisha Bent, Tri Le, Alana Christie, Zabi Wardak, Yull Arriaga, Kevin Courtney, Hans Hammers, Samuel Barnett, Bruce Mickey, Toral Patel, Tony Whitworth, Strahinja Stojadinovic, Raquibul Hannan, Lucien Nedzi, Robert Timmerman, James Brugarolas
BACKGROUND: Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known. PATIENTS AND METHODS: A retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created...
December 5, 2018: Clinical Genitourinary Cancer
Haruhiko Yamazaki, Takeshi Kishida, Go Noguchi, Hiroyuki Iwasaki, Nobuyasu Suganuma, Katsuhiko Masudo, Hirotaka Nakayama, Toshinari Yamashita, Takashi Yamanaka, Yuko Sugawara, Yuka Matsubara, Kaori Kohagura, Yasushi Rino, Munetaka Masuda
The occurrence of renal tumors originating from thyroid cancer is extremely rare with a few effective treatments for renal metastases. Here, we report the cases of two patients with differentiated thyroid cancer who underwent nephrectomy for a metastatic kidney tumor. Case 1 was a 74-year-old man who was diagnosed with right kidney tumor 10 years after initial surgery for papillary thyroid cancer (PTC). Right nephrectomy was performed, and the pathology was metastatic PTC. Case 2 was a 68-year-old woman who was diagnosed with left kidney tumor 24 years after surgery for follicular thyroid carcinoma (FTC)...
2018: Case Reports in Endocrinology
Clara Santos-Cuevas, Guillermina Ferro-Flores, Francisco O García-Pérez, Nallely Jiménez-Mancilla, Gerardo Ramírez-Nava, Blanca Ocampo-García, Myrna Luna-Gutiérrez, Erika Azorín-Vega, Jenny Davanzo, Irma Soldevilla-Gallardo
SPECT/CT images in patients have demonstrated the ability of [99m Tc]Tc-EDDA/HYNIC-Lys(Nal)-Urea-Glu ([99m Tc]Tc-iPSMA) to detect tumors and metastases of prostate cancer. Considering that theranostics combines the potential of therapeutic and diagnostic radionuclides in the same molecular probe, the aim of this research was to estimate the biokinetics and dosimetry of 177 Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu (177 Lu-iPSMA) in healthy subjects and analyze the response in patients receiving 177 Lu-iPSMA therapeutic doses...
2018: Contrast Media & Molecular Imaging
Masayuki Ohashi, Toru Hirano, Kei Watanabe, Kazuhiro Hasegawa, Takui Ito, Keiichi Katsumi, Hirokazu Shoji, Tatsuki Mizouchi, Ikuko Takahashi, Takao Homma, Naoto Endo
Study Design: Retrospective case series. Purpose: To investigate the oncological outcomes, including distant relapse, after en bloc spondylectomy (EBS) for spinal metastases in patients with a minimum of 2-year follow-up. Overview of Literature: Although EBS has been reported to be locally curative and extend survival in select patients with spinal metastases, detailed reports regarding the control of distant relapse after EBS are lacking...
November 29, 2018: Asian Spine Journal
K Bensalah, L Albiges, J-C Bernhard, P Bigot, T Bodin, R Boissier, J-M Correas, P Gimel, J-F Hetet, J-A Long, F-X Nouhaud, I Ouzaïd, N Rioux-Leclercq, A Méjean
OBJECTIVE: To update the French guidelines on kidney cancer. METHODS: A systematic review of the literature between 2015 and 2018 was performed. The most relevant articles regarding the diagnosis, the classification, surgical treatment, medical treatment and follow-up of kidney cancer were retrieved and included in the new guidelines. The guidelines were updated with corresponding levels of evidence. RESULTS: Thoraco-abdominal CT scan with injection is the best radiological exam for the diagnosis of kidney cancer...
November 2018: Progrès en Urologie
Donghui Zhou, Khuchtumur Bum-Erdene, David Xu, Degang Liu, Doug Tompkins, Rania S Sulaiman, Timothy W Corson, John M Chirgwin, Samy O Meroueh
Bone is a common site of metastasis for breast, prostate, lung, kidney and other cancers. Bone metastases are incurable, and substantially reduce patient quality of life. To date, there exists no small-molecule therapeutic agent that can reduce tumor burden in bone. This is partly attributed to the lack of suitable in vitro assays that are good models of tumor growth in bone. Here, we take advantage of a novel ex vivo model of bone colonization to report a series of pyrrolopyrazolone small molecules that inhibit cancer cell invasion and ex vivo tumor growth in bone at single-digit micromolar concentration...
November 16, 2018: Bioorganic & Medicinal Chemistry
Bimal Bhindi, E Jason Abel, Laurence Albiges, Karim Bensalah, Stephen A Boorjian, Siamak Daneshmand, Jose A Karam, Ross J Mason, Thomas Powles, Axel Bex
CONTEXT: The role of cytoreductive nephrectomy (CN) in the management of metastatic renal cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. OBJECTIVE: To assess if CN versus no CN is associated with improved overall survival (OS) in patients with mRCC treated in the TT era and beyond, characterize the morbidity of CN, identify prognostic and predictive factors, and evaluate outcomes following treatment sequencing. EVIDENCE ACQUISITION: Medline, EMBASE, and Cochrane databases were searched from inception to June 4, 2018 for English-language clinical trials, cohort studies, and case-control studies evaluating patients with mRCC who underwent and those who did not undergo CN...
October 25, 2018: European Urology
Sarah Stefanowicz, Kristin Stützer, Sebastian Zschaeck, Annika Jakobi, Esther G C Troost
BACKGROUND: Neoadjuvant radio(chemo)therapy of non-metastasized, borderline resectable or unresectable locally advanced pancreatic cancer is complex and prone to cause side-effects, e.g., in gastrointestinal organs. Intensity-modulated proton therapy (IMPT) enables a high conformity to the targets while simultaneously sparing the normal tissue such that dose-escalation strategies come within reach. In this in silico feasibility study, we compared four IMPT planning strategies including robust multi-field optimization (rMFO) and a simultaneous integrated boost (SIB) for dose-escalation in pancreatic cancer patients...
November 22, 2018: Radiation Oncology
Spencer C Behr, Rahul Aggarwal, Henry F Van Brocklin, Robert R Flavell, Kenneth Geo, Eric J Small, Joseph Blecha, Salma Jivan, Thomas A Hope, Jeffrey P Simko, John Kurhanewicz, Susan M Noworolski, Natalie J Korn, Romelyn De Los Santos, Matthew R Cooperberg, Peter R Carroll, Hao G Nguyen, Kirsten L Greene, Beatrice Langton-Webster, Clifford E Berkman, Youngho Seo
Prostate-specific membrane antigen (PSMA) targeting agents comprise a rapidly emerging class of radiopharmaceuticals for prostate cancer diagnostic imaging. Unlike most other PSMA agents with a urea-backbone, CTT1057 is based on a phosphoramidate scaffold that irreversibly binds to PSMA. We conducted a first-in-human Phase I study of CTT1057 in patients with localized and metastatic prostate cancer. Methods: Two patient cohorts were recruited. Cohort A were patients with biopsy-proven localized prostate cancer preceding radical prostatectomy, and cohort B were patients with metastatic castrate resistant prostate cancer...
November 21, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Ashkan Tadayoni, Anna K Paschall, Ashkan A Malayeri
Accurate detection of lymph node involvement on pre-operative imaging in patients diagnosed with renal cell carcinoma (RCC) is critical for determination of disease stage, one of the most significant prognostic factors in RCC. The presence of lymph node involvement in RCC doubles a patient's risk of distant metastasis and significantly reduces their 5-year survival. Currently, lymph node involvement in patients with RCC is evaluated with numerous modalities, with rapid advancements occurring across these modalities...
October 2018: Translational Andrology and Urology
Satoshi Kato, Hideki Murakami, Satoru Demura, Katsuhito Yoshioka, Noriaki Yokogawa, Noritaka Yonezawa, Takaki Shimizu, Norihiro Oku, Ryo Kitagawa, Hiroyuki Tsuchiya
No abstract text is available yet for this article.
November 15, 2018: World Neurosurgery
Costantino Ricci, Martina S Rossi, Roberta De Stefano, Michelangelo Fiorentino, Francesco Vasuri
CASE PRESENTATION: A 55-year-old man with a history of basaloid squamous cell carcinoma of the oropharynx with laterocervical lymph node metastases 6 years before (and treated with chemoradiation) presented with flank pain and hematuria. Computed tomography scan found a renal lesion, with radiological features more suspicious for primitive renal neoplasia. Histopathological and immunohistochemical examination after surgical excision revealed a basaloid squamous cell carcinoma involving renal parenchyma...
November 2018: Urologia
Jeff John, Alessandro P Aldera, Sunil Sinha, John Lazarus
Introduction: Cancers of the kidney, arising from either the renal parenchymal tissue or the renal pelvis, is among the 13 commonest types of malignancy globally, accounting for between 3% and 4% of all newly diagnosed cancers. Renal cell carcinoma (RCC) accounts for 85% of all malignant renal neoplasms. We present a rare case of an RCC directly extending into the renal pelvicalyceal system and with a thrombus within the ureter. Case Presentation: A 39-year-old woman presented with a long-standing history of worsening left flank pain, intermittent visible hematuria, and a fullness in the left flank...
2018: Journal of Endourology Case Reports
Shotaro Yasuoka, Tsutomu Hamasaki, Eigo Kuribayashi, Masato Nagasawa, Takanori Kawaguchi, Yoji Nagashima, Yukihiro Kondo
RATIONALE: Collecting duct carcinoma (CDC) is a rare type of nonclear renal cell carcinoma, often presenting at an advanced stage of the disease, and standard treatment guidelines have not been established. PATIENT CONCERNS: A 73-year-old man was admitted to our hospital with complaints of fever and lower right back pain. DIAGNOSES: Computed tomography revealed a poorly defined tumor of the right kidney without metastasis. The patient underwent right radical nephrectomy and was diagnosed with clinical stage T1bN0M0 renal cancer; the pathological findings showed collecting duct carcinoma...
November 2018: Medicine (Baltimore)
Akira Joraku, Kentaro Hatano, Koji Kawai, Shuya Kandori, Takahiro Kojima, Nobuyoshi Fukumitsu, Tomonori Isobe, Yutaro Mori, Muneyuki Sakata, Tadashi Hara, Katsuhiro Nasu, Manabu Minami, Yuichi Iizumi, Hiroyuki Nishiyama
OBJECTIVE: We conducted the present phase I/IIa positron emission tomography (PET) imaging study with 89 Zr conjugated with desferroxamine-IAB2M (89 Zr-Df-IAB2M), an anti-prostate-specific membrane-antigen minibody, to assess its safety and feasibility in patients with urological cancer. METHODS: 89 Zr-Df-IAB2M was synthetized by IBA Molecular (Somerset, NJ, USA) and transported by air to Tsukuba Molecular Imaging Center (Tsukuba, Ibaraki, Japan).17 patients received 74 MBq (2 mCi) of 89 Zr-Df-IAB2M at total mass doses of 10 mg...
November 7, 2018: Annals of Nuclear Medicine
Sven Hausner, Richard J Bold, Lina Y Cheuy, Helen K Chew, Megan E Daly, Ryan A Davis, Cameron C Foster, Edward J Kim, Julie L Sutcliffe
PURPOSE: The study was undertaken to develop and evaluate the potential of an integrin αv β6 -binding peptide (αv β6 -BP) for noninvasive imaging of a diverse range of malignancies with positron emission tomography (PET). EXPERIMENTAL DESIGN: The peptide αv β6 -BP was prepared on solid phase and radiolabeled with 4-[18 F]fluorobenzoic acid. In vitro testing included ELISA, serum stability, and cell binding studies using a paired αv β6 -expressing and αv β6 -null cell lines...
November 6, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Hendrik Rathke, Paul Flechsig, Walter Mier, Marcus Bronzel, Eleni Mavriopoulou, Manuel Roehrich, Markus Hohenfellner, Frederik L Giesel, Uwe L Haberkorn, Clemens Kratochwil
Due to different physical properties, the beta-emitters 177 Lu and 90 Y offer specific radiation-biological advantages in dedicated clinical situations, respectively. Our objective was to introduce 90 Y-PSMA-617 to clinical application, providing additional avenues for personalized medicine. Here we present our dosimetry-estimate for 90 Y-PSMA-617, report initial clinical experiences and discuss the advantages and drawbacks of varying the beta-emitter in prostate-specific membrane antigen (PSMA) targeting radioligand therapy (RLT)...
November 2, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Alexey V Baldin, Alena N Grishina, Dmitry O Korolev, Ekaterina B Kuznetsova, Marina O Golovastova, Alexey S Kalpinskiy, Boris Y Alekseev, Andrey D Kaprin, Dmitry V Zinchenko, Lyudmila V Savvateeva, Vladimir A Varshavsky, Evgeni Yu Zernii, Andrey Z Vinarov, Alexandr V Bazhin, Pavel P Philippov, Andrey A Zamyatnin
Renal cell carcinoma (RCC) is the second-most common uronephrological cancer. In the absence of specific symptoms, early diagnosis of RCC is challenging. Monitoring of the aberrant expression of tumour-associated antigens (TAAs) and related autoantibody response is considered as a novel approach of RCC diagnostics. The aim of this study was to examine the aberrant expression of arrestin-1 in renal tumours, to investigate the possible epigenetic mechanism underlying arrestin-1 expression, and to assess the frequency of anti-arrestin-1 autoantibody response...
October 30, 2018: Biochimie
Diego A S Toesca, Amanda J Koong, Rie von Eyben, Albert C Koong, Daniel T Chang
Purpose: This study aimed to report on our institutional experience in the use of stereotactic body radiation therapy (SBRT) for the treatment of adrenal gland metastases. Specifically, we examined the outcomes and toxicity from this treatment modality on adjacent organs at risk. Methods and Materials: Data were retrieved from patients with adrenal metastases who were treated with SBRT between 2008 and 2017. Patients with primary adrenal malignancies were excluded...
October 2018: Advances in Radiation Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"